Objective: To compare the efficacy of vaginal with oral misoprostol in termination of second-trimester pregnancy after pretreatment with mifepristone. Methods: Women requesting termination of second-trimester pregnancy were randomized into two groups. Thirty-six to 48 hours after oral administration of 200 mg of mifepristone, women were given either oral or vaginal misoprostol 200 μg every 3 hours for a maximum of five doses in the first 24 hours. Women receiving oral misoprostol also were given a vaginal placebo (vitamin B6), whereas those receiving vaginal misoprostol were given an oral placebo. If they failed to abort, a second course was given by the same route. Results: The median induction-abortion interval in the vaginal group (9 hou...
OBJECTIVES: The primary objective of the study was to compare the Induction Abortion Interval (IAI...
Objective: Comparing sublingual and vaginal misoprostol in second trimester pregnancy termination. M...
Objective: To compare the efficacy, side effects and acceptability of sublingual and vaginal misopro...
It is known that when misoprostol is given at 200 μg every 3 h after mifepristone pretreatment, the ...
A prospective randomized trial was conducted in 140 women to compare the efficacy of vaginal gemepro...
A prospective randomized trial was conducted in 148 women to compare the efficacy of two regimens of...
Introduction: During the last decade, medical methods for second trimester abortion have considerabl...
The aim: To study the efficacy and safety of combined mifepristone and misoprostol used in second-tr...
The aim: To study the efficacy and safety of combined mifepristone and misoprostol used in second-tr...
Background: Misoprostol is a PGE1 analogue is used to terminate pregnancies with great success. It i...
disadvantage of medical abortion is the longer duration of bleeding compared with surgical abortion ...
Abstract- The search continues for a safe effective and cheap method for mid-trimester termination o...
The aim: To study the efficacy and safety of combined mifepristone and misoprostol used in second-tr...
OBJECTIVE: Mifepristone-misoprostol medical abortion has been approved in the United States since 20...
Contains fulltext : 69349.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
OBJECTIVES: The primary objective of the study was to compare the Induction Abortion Interval (IAI...
Objective: Comparing sublingual and vaginal misoprostol in second trimester pregnancy termination. M...
Objective: To compare the efficacy, side effects and acceptability of sublingual and vaginal misopro...
It is known that when misoprostol is given at 200 μg every 3 h after mifepristone pretreatment, the ...
A prospective randomized trial was conducted in 140 women to compare the efficacy of vaginal gemepro...
A prospective randomized trial was conducted in 148 women to compare the efficacy of two regimens of...
Introduction: During the last decade, medical methods for second trimester abortion have considerabl...
The aim: To study the efficacy and safety of combined mifepristone and misoprostol used in second-tr...
The aim: To study the efficacy and safety of combined mifepristone and misoprostol used in second-tr...
Background: Misoprostol is a PGE1 analogue is used to terminate pregnancies with great success. It i...
disadvantage of medical abortion is the longer duration of bleeding compared with surgical abortion ...
Abstract- The search continues for a safe effective and cheap method for mid-trimester termination o...
The aim: To study the efficacy and safety of combined mifepristone and misoprostol used in second-tr...
OBJECTIVE: Mifepristone-misoprostol medical abortion has been approved in the United States since 20...
Contains fulltext : 69349.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
OBJECTIVES: The primary objective of the study was to compare the Induction Abortion Interval (IAI...
Objective: Comparing sublingual and vaginal misoprostol in second trimester pregnancy termination. M...
Objective: To compare the efficacy, side effects and acceptability of sublingual and vaginal misopro...